Headlines about Enanta Pharmaceuticals (NASDAQ:ENTA) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.2244072767513 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news articles that may have impacted Accern’s analysis:

Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 0.67% during midday trading on Friday, reaching $39.16. 117,633 shares of the company’s stock traded hands. The company’s market capitalization is $747.17 million. Enanta Pharmaceuticals has a 1-year low of $21.00 and a 1-year high of $41.20. The firm’s 50 day moving average price is $37.42 and its 200-day moving average price is $32.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. The business had revenue of $7.51 million for the quarter, compared to the consensus estimate of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business’s quarterly revenue was down 46.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) earnings per share. Equities analysts expect that Enanta Pharmaceuticals will post $0.90 EPS for the current year.

Several research firms recently issued reports on ENTA. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. J P Morgan Chase & Co reissued an “overweight” rating and issued a $38.00 target price (up from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday. Robert W. Baird upped their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 8th. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a research report on Tuesday, July 11th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $36.00.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/13/enanta-pharmaceuticals-nasdaqenta-given-daily-coverage-optimism-score-of-0-18.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.